Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Apr
4
2016
Second Circuit Narrowly Applies Supreme Court’s Decision in Omnicare Sheppard, Mullin, Richter & Hampton LLP
Nov
13
2023
CMS Promotes Competition, Transparency, Health Equity and More in the CY2025 Medicare Advantage and Part D Proposed Rule Sheppard, Mullin, Richter & Hampton LLP
Nov
18
2020
Green Wave: The Latest Election Cycle Brings Hope for Standardized Cannabis Legalization Sheppard, Mullin, Richter & Hampton LLP
Nov
23
2020
Los Angeles County Restricts In-Person Dining Due to Surge in COVID-19 Cases Sheppard, Mullin, Richter & Hampton LLP
Dec
9
2010
Adjusting the Inequitable Conduct Doctrine: Federal Circuit Hears Oral Arguments En Banc in Therasense Sheppard, Mullin, Richter & Hampton LLP
Apr
29
2021
“Buy American” Update: Essential Medicines May Continue to Come From Abroad (For Now) Sheppard, Mullin, Richter & Hampton LLP
Jan
12
2022
FDA Releases Guidances on Transition Plan for Devices Distributed Under Emergency Use Authorization (EUA) or Enforcement Policies During COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Feb
5
2014
Changes To California Title 24 Energy Use Requirements Effective July 1, 2014 Sheppard, Mullin, Richter & Hampton LLP
Jan
25
2019
TRICARE: Defense Health Agency Issues Request for Information Regarding Formulary Management – Submission Deadline: February 5, 2019 Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2019
Second Circuit Affirms “Snap” Removal Practice Sheppard, Mullin, Richter & Hampton LLP
Nov
3
2014
Beginning to Close the POM Circle? – POM Wonderful and Drug Advertising: JHP Pharmaceuticals Sheppard, Mullin, Richter & Hampton LLP
Dec
23
2014
U.S. Patent and Trademark Office Clarifies “Patent Eligible Subject” Matter in its Recent Guidance in Light of Alice Sheppard, Mullin, Richter & Hampton LLP
Jan
23
2015
FDA Issues Guidance for Low-Risk General Wellness Products Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2022
California’s Newly Adopted “Safe Harbor” Warning Label for Acrylamide In Foods Turns Up the Heat In Ongoing First Amendment Challenge to Proposition 65 Sheppard, Mullin, Richter & Hampton LLP
Jan
20
2023
FDA Approval Mifepristone REMS Program Modification Expands Patient Access to Abortion Care Sheppard, Mullin, Richter & Hampton LLP
Mar
15
2023
CMS Releases First Set of Part B Rebatable Drugs for Coinsurance Adjustment Under IRA Sheppard, Mullin, Richter & Hampton LLP
Jun
15
2023
Access to Abortion Pill on the Precipice: A Deep Dive into the Federal Court Rulings that will Decide the Fate of Mifepristone Sheppard, Mullin, Richter & Hampton LLP
Apr
6
2020
CMS “Hospitals Without Walls” Waiver: Looking To ASCs to Provide Relief Sheppard, Mullin, Richter & Hampton LLP
May
15
2020
Not So Fast – FDA Retracts Authorization for Some Respirators Made in China Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2020
A Year of Living Dangerously: 2020 and Maneuvers on the 340B Drug Pricing Program Battlefield Sheppard, Mullin, Richter & Hampton LLP
Dec
2
2020
Eleventh Hour Rulemaking: HHS Eliminates Safe Harbor Protections for PBM Drug Rebates; and Creates Two New Safe Harbors for Point-of-Service Discounts and PBM Fixed-Fee Arrangements Sheppard, Mullin, Richter & Hampton LLP
Jan
29
2021
NLRB’s Division of Advice Determines Certain Workers in the Cannabis Industry Are Exempt From Federal Labor Law Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2011
A MATRIXX Revolution, Part II: Supreme Court affirms Ninth Circuit's holding that Life Science Companies Cannot Rely On a Statistical Significance Standard When Deciding Whether Adverse Event Reports are Material for the Purpose of Securities Disclosures Sheppard, Mullin, Richter & Hampton LLP
Dec
20
2017
California Court of Appeal Affirms Judgment Finding No Duty to Defend Drug Manufacturer in Lawsuits Alleging Increased Opioid Usage Sheppard, Mullin, Richter & Hampton LLP
Oct
5
2021
California Jury Awards Millions to Cannabis Company in Antitrust Case Sheppard, Mullin, Richter & Hampton LLP
Nov
1
2021
Florida Imposes Criminal Penalties for Improper Processing of DNA Sheppard, Mullin, Richter & Hampton LLP
Jul
11
2013
Farming Solar Rays: County Decision to Approve Industrial-Scale Solar on Williamson Act Lands OK'd Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2021
CMS Suspends Vaccine Mandate Enforcement for Healthcare Workers Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins